Company news
Hunan Nucien Pharmaceutical Co. Ltd. news in 2025
Hunan Nucien Pharmaceutical Co. Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
December 26, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
December 10, 2025
Report for Q3 2025
October 30, 2025
Announcement on Early Returning of Raised Funds Temporarily Used for Supplementing Current Capital
October 21, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
October 10, 2025
Announcement on Serious Abnormal Fluctuations in Stock Trading
October 9, 2025
Announcement on Receiving Notice of Litigation Filing from China Securities Regulatory Commission
September 30, 2025
Announcement on Progress in Planning Major Asset Restructuring
September 26, 2025
Announcement on Shareholding Reduction Plan for Shareholders
September 24, 2025
Announcement on Resolutions of the 16th Meeting of the 2nd Board of Supervisors
September 22, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Hunan Jurisdiction and Semi-annual Performance Briefing
September 12, 2025
Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase
August 29, 2025
Special Report on Semi-annual Deposit and Use of Raised Funds in 2025
August 28, 2025
Indicative Announcement on Planning Major Asset Restructuring and Signing the "Agreement of Intention for Acquisition"
August 26, 2025
Announcement on Abnormal Fluctuations in Stock Trading
July 30, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 13, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
May 30, 2025
Announcement on Using Extra Raised Funds to Permanently Supplement Current Capital
May 23, 2025
Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders without Sales Limit Concerning Shares Repurchase
May 7, 2025
Announcement on Proposed Cancellation of Subsidiary
April 29, 2025